Literature DB >> 15127409

Exercise echocardiography reflects cumulative anthracycline exposure during childhood.

Elizabeth Smibert1, John B Carlin, Suzanna Vidmar, Lynette C Wilkinson, Melissa Newton, Robert G Weintraub.   

Abstract

BACKGROUND: Low and moderate dose anthracycline therapy used in current treatment protocols, may be associated with subclinical abnormalities of cardiac function and late presentation with congestive heart failure. Exercise echocardiography is a useful and non-invasive means of uncovering latent cardiac dysfunction in other settings. The purpose of this study is to determine whether exercise echocardiography has the potential to detect subclinical abnormalities of cardiac function in children treated with anthracyclines. PROCEDURE: One hundred ten children previously treated with anthracycline, in remission and off treatment for >12 months were assessed, together with 31 control subjects. Each subject had a resting ECG and echocardiogram performed, and following exercise on a treadmill according to the Bruce protocol, a repeat echocardiogram was performed.
RESULTS: Cumulative anthracycline dose was the only patient variable related to any of the outcome measures. Resting fractional shortening was normal in the majority of treated patients but was inversely related to cumulative anthracycline dose (rate of decline 1.2%/100 mg/m(2)). Following peak exercise, the inverse relationship between fractional shortening and anthracycline dose was more pronounced (rate 2.7%/100 mg/m(2)).
CONCLUSIONS: Higher anthracycline doses are associated with a greater difference in peak fractional shortening between treated subjects and controls. Exercise echocardiography is a simple, relatively inexpensive tool that may enhance the detection of latent cardiac dysfunction after anthracycline administration during childhood. Copyright 2004 Wiley-Liss, inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15127409     DOI: 10.1002/pbc.20016

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

Review 1.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

2.  Exercise capacity in apparently healthy survivors of cancer.

Authors:  E De Caro; F Fioredda; M G Calevo; A Smeraldi; M Saitta; G Hanau; M Faraci; F Grisolia; G Dini; G Pongiglione; R Haupt
Journal:  Arch Dis Child       Date:  2005-09-27       Impact factor: 3.791

Review 3.  Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.

Authors:  Mohamed Aissiou; Delphine Périé; Farida Cheriet; Nagib S Dahdah; Caroline Laverdière; Daniel Curnier
Journal:  Int J Cardiovasc Imaging       Date:  2013-06-07       Impact factor: 2.357

Review 4.  Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.

Authors:  Michel G Khouri; Michael R Klein; Eric J Velazquez; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

5.  Mitochondrionopathy phenotype in doxorubicin-treated Wistar rats depends on treatment protocol and is cardiac-specific.

Authors:  Gonçalo C Pereira; Susana P Pereira; Claudia V Pereira; José A Lumini; José Magalhães; António Ascensão; Maria S Santos; António J Moreno; Paulo J Oliveira
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

Review 6.  The Utility of Cardiac Reserve for the Early Detection of Cancer Treatment-Related Cardiac Dysfunction: A Comprehensive Overview.

Authors:  Stephen Foulkes; Guido Claessen; Erin J Howden; Robin M Daly; Steve F Fraser; Andre La Gerche
Journal:  Front Cardiovasc Med       Date:  2020-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.